• Home
• Partneringtools
• Reports

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Consulting
• Jobs
• Forums

• About us
• Products
• Newsletter

Pharmalicensing Ltd
is a division of

News of the day

Industry news search

Recent news

To keep up to date with news from this category use our

Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
August 26, 2008-Seattle, WA - Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction...

Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
August 26, 2008 -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has secured $2.0 million through the sale of approximately 4.7 million shares of common stock at $0.42 per share under its June 2007...

Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
NEW YORK-- August 26, 2008--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2...

DIAGNOCURE RECEIVES APPROVAL FROM THE U.S. REGULATORY AUTHORITIES AND LAUNCHES ITS PREVISTAGETM GCC COLORECTAL CANCER STAGING TEST
QUEBEC CITY (Canada), August 26, 2008 -- DiagnoCure Oncology Laboratories, based in West Chester, PA, a wholly-owned subsidiary of DiagnoCure Inc., announced today that it has received the U.S. CLIA certification...

Adagio Trial Results Show Teva's Azilect
Jerusalem, Israel, August 26, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of...

NEXMED ANNOUNCES DECISION FOR NM100060
East Windsor, NJ, August 26, 2008 -- NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT

CLINILABS PROVIDED CENTRAL SCORING SERVICES TO SUCCESSFUL PHASE III VANDA STUDY
New York, NY (August 26, 2008) - Clinilabs, Inc. provided centralized data processing services to Vanda Pharmaceuticals Inc., a biopharmaceutical company, for a Phase III study of tasimelteon (VEC-162), an...

ADAGIO trial results show Azilect
August 26, 2008 -- Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced today that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological...

Morphotek,
Exton, PA, August 26, 2008 - Morphotek

Curis Announces Dosing of First Patient in Phase I Clinical Trial of CUDC-101
CAMBRIDGE, Mass.--Aug. 26, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced that the first patient...

NOVAVAX ANNOUNCES FAVORABLE RESULTS FROM PHASE I/IIa PANDEMIC INFLUENZA VACCINE PROGRAM
ROCKVILLE, MD (August 26, 2008) - Novavax, Inc. (NASDAQ: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine...

ANTHERA PHARMACEUTICALS ADVANCES GLOBAL DEVELOPMENT STRATEGY FOR VARESPLADIB IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH THE INITIATION OF FRANCIS TRIAL
SAN MATEO, CA - August 25, 2008 - Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute...

Phase 1b/2a Program Commences for RVX-208
Calgary, AB, August 25, 2008 - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low...

Oxygen Biotherapeutics, Inc. to Meet With FDA to Discuss Proposed Phase II-b Oxycyte Clinical Trial
COSTA MESA, Calif., Aug 25, 2008-- Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company will meet with the U.S. Food and Drug Administration (FDA) to discuss two remaining issues that the agency...

Isolagen Reports Positive Results from Open Label, Phase II Study of Isolagen Therapy(TM) of the Full Face Regarding the Treatment of Wrinkles and Skin Quality Characteristics
EXTON, Pa., August 25, 2008 -- Isolagen(TM), Inc. (Amex: ILE) announced today results from a prospective, open label, Phase II study (IT-R-007) of Isolagen Therapy(TM) for the treatment of facial wrinkles and creases in...

Patients Taking Cymbalta
INDIANAPOLIS, August 25, 2008 -- Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour...

HUMAN GENOME SCIENCES COMPLETES ENROLLMENT IN RANDOMIZED PHASE 2 TRIAL OF HGS-ETR1 IN NON-SMALL CELL LUNG CANCER
ROCKVILLE, Maryland - August 22, 2008 - Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1...

Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
LEXINGTON, Mass., August 22, 2008 -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal...

Santhera's 2008 Interim Results Reflect Advances in Clinical Development and Preparation for First Product Launch
August 22, 2008, Santhera will host a conference call webcasted on www.santhera.com/webcasts. Anyone interested in participating may join the conference using the dial-in +41 (0)44 580 73 80.

Synta Announces Publication of Elesclomol Mechanism of Action Results in AACR Journal Molecular Cancer Therapeutics
LEXINGTON, Mass.----Aug. 22, 2008--Synta Pharmaceuticals Corp., (NASDAQ: SNTA) today announced the publication of new findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that...

Ash Access Technology Completes AZEPTIC Trial for Zuragen(TM) Injection
AUGUST 22, 2008 7:52 AM EST (Lafayette, Indiana) - - - Ash Access Technology, Inc., a privately held specialty pharmaceutical / medical device company focused on the development and commercialization of proprietary...

Clinical development of ELACYT in haematology expanded
Oslo, Norway, August 22, 2008--Dose limiting toxicity has been observed in the Intravenous CP-4126 dose escalating Phase I study. The study continues in order to establish the recommended dose for Phase II.

Bayer And Onyx Begin Enrollment In Storm Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer
August 21, 2008-Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun enrolling patients in the STORM Sorafenib as Adjuvant Treatment in the...

Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
ROCKVILLE, MD - (August 21, 2008) - Novavax, Inc. (Nasdaq: NVAX) today announced that the Company will hold an investor conference call to discuss results from the Phase I/IIa human clinical trial of Novavax's H5N1...

Metvix
Oslo, Norway, 21 August, 2008 - Organ transplant recipients on long-term immunosuppressive therapy are at increased risk of non-melanoma skin cancer (NMSC), including actinic keratoses (AK). AK is the most common...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
TOKYO and INDIANAPOLIS, August 21, 2008 -- A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute coronary syndromes (ACS) managed with an...

Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer and Fundamental Research Corporation Initiates Analyst Coverage
Vancouver, BC (August 21, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases,...

GENMAB REACHES FIFTH MILESTONE IN OFATUMUMAB COLLABORATION
Copenhagen, Denmark; August 21, 2008 - Genmab A/S (OMX: GEN) announced today it has reached the fifth milestone for ofatumumab (HuMax-CD20

BIOGEN IDEC INITIATES PHASE III CLINICAL TRIAL FOR ADENTRI
Cambridge, Mass., August 21, 2008 - Biogen Idec (Nasdaq: BIIB) today announced the initiation of a Phase III clinical trial of intravenous (IV) ADENTRI

New Trial to Evaluate Nexavar
Leverkusen, August 21, 2008 - Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the start of a Phase III study with Nexavar

Auris Medical reporting results of phase I/II clinical trial with AM-101
August 21, 2008-- Auris Medical reported the results of the first clinical trial with AM-101, its investigational drug for the treatment of inner ear tinnitus. The double blind, randomised clinical trial with placebo...

DELCATH EXPANDS PHASE III TRIAL FOR METASTATIC MELANOMA
NEW YORK, NY - August 21, 2008 - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Swedish Medical Center in Englewood, Colorado, has joined Delcath's Phase III clinical trial for the treatment of metastatic...

New Trial to Evaluate Nexavar
Leverkusen, August 21, 2008 - Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the start of a Phase III study with Nexavar

MEDINET STARTS COMMERCIALIZATION OF NOVEL CANCER IMMUNOTHERAPY TECHNOLOGY IN JAPAN UTILIZING MAXCYTE'S CELL LOADING SYSTEM
Gaithersburg, MD, USA and Yokohama, Japan - August 20, 2008 - MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announced today that Medinet will begin commercializing a novel cell engineering approach, utilizing...

BIOVEX ANNOUNCES REGULATORY CLEARANCE TO COMMENCE A CLINICAL STUDY WITH IMMUNOVEXHSV2; A VACCINE CANDIDATE FOR GENITAL HERPES
Woburn, MA - August 20, 2008 - BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products...

Biopartners to present 3-year safety and efficacy trial data for its once-a-week sustained release recombinant human growth hormone (SR-hGH; LB03002) at major scientific conferences
Baar, Switzerland 20 August 2008: Biopartners has announced that it has been granted an oral presentation to share the three year safety and efficacy data on its once-a-week sustained-release human growth hormone...

ACTIVX BIOSCIENCES, INC. ANNOUNCES POSITIVE PHASE IB and IIA CLINICAL TRIAL RESULTS FOR KRP-104, A FLEXIBLE DOSING DPP-4 INHIBITOR FOR TYPE 2 DIABETES
La Jolla, Calif., --August 20, 2008 Activx Biosciences, Inc., a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., announced today topline results from their Phase Ib and Phase IIa clinical trials...

12 MONTH PHASE 3 TRIAL FINDS BRONCHITOL SAFE IN BRONCHIECTASIS
August 20, 2008-Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no...

RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial
BETHESDA, Md., Aug 20, 2008 -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a...

Biomarker in Patient Samples from a Clinical Trial of LOR-2040 Combined with Capecitabine in Breast Cancer
TORONTO, CANADA - August 20, 2008 - Lorus Therapeutics Inc, (TSX: LOR, AMEX: LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the...

Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients
CAMBRIDGE, Mass., Aug 19, 2008-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Company has reached agreement with U.S. and E.U. regulatory authorities to proceed with the REALIZE trial, a...

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
PRINCETON, N.J. & REDWOOD CITY, Calif., August 19, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced an agreement for the global development and commercialization of...

Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Leverkusen, Germany and Tarrytown, NY, August 19, 2008 - Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that patients with wet age-related macular degeneration (AMD) receiving...

Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
PALO ALTO, Calif., Aug. 19-- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the Journal of Cardiovascular Electrophysiology has published a study of ranolazine showing that ranolazine significantly (p<0.001)...

Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study at World Pain Congress in Scotland
GLASGOW, SCOTLAND - August 19, 2008 - Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY

Invitrogen Launches Legionella Test to Streamline Surveillance
CARLSBAD, Calif., August 19, 2008 -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, announced today the launch of its Dynabeads(R) MAX...

Vion Pharmaceuticals Enters into Agreement with HOVON to Conduct a Phase III Clinical Trial of Cloretazine
NEW HAVEN, CT, August 19, 2008 - VION PHARMACEUTICALS, INC. (PINK SHEETS:VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON")...

Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Leverkusen, Germany and Tarrytown, NY, August 19, 2008 - Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that patients with wet age-related macular degeneration (AMD) receiving...

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Tarrytown, NY and Leverkusen, Germany (August 19, 2008) - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that patients with wet age-related macular degeneration (AMD) receiving...

Yakult Honsha to Commence ThermoDox(R) Development Program in Japan
COLUMBIA, Md., Aug 18, 2008 -- Celsion Corporation (NASDAQ: CLSN: Michael H. Tardugno, President and Chief Executive Officer) and Yakult Honsha Co., Ltd. (Yakult: Mr. Sumiya Hori, President) today announce that Yakult...

Asuragen, Inc. Launches Signature
Austin, Texas - August 18, 2008 - Asuragen, Inc. announced today the launch of Signature

F2G Ltd completes
Manchester, UK, 18th August 2008 - F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the completion of a

AMRI Initiates Phase I Study of Proprietary Oncology Drug Candidate
Albany, NY (August 18, 2008)--AMRI (NASDAQ: AMRI) today announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed to kill cancer cells by preventing cell mitosis.

Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen
THE WOODLANDS, Texas--August 18, 2008--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that based on the robust efficacy demonstrated by Proellex

BRONCHITOL PHASE 3 CYSTIC FIBROSIS TRIAL COMPLETES RECRUITMENT
August 18, 2008-Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that the first pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has completed enrolment.

Swedish test identifies patients with increased risk for kidney transplant rejection
August 18, 2008--The Swedish biotech company AbSorber recently received FDA approval in the U.S. for its patented transplantation test XM-ONE

PROSOLV
Indianapolis, IN - August 18, 2008 - ProSolv CardioVascular, a FUJIFILM company, is pleased to announce the immediate availability of ProSolv

Moberg Derma reports promising phase III clinical results for its product candidate K301 against seborrheic dermatitis
August 18, 2008 -- Moberg Derma is today reporting promising results from a phase III study for K301 against seborrheic dermatitis. The study showed that K301 was significantly superior to placebo for several key...

Logical Therapeutics, Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
WALTHAM, Mass., August 18, 2008 -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today the...

Dyax Announces DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA4(R))
CAMBRIDGE, Mass.--Aug. 18, 2008--Dyax Corp. (NASDAQ:DYAX) announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 (ecallantide) for...

Stellar Pharmaceuticals Inc. Announces Successful Completion of Watson's Pilot Clinical Study
LONDON, ONTARIO-- Aug. 18, 2008 - Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc ("Watson"), has successfully concluded...

Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well
BELLEVILLE, ON, August 18, 2008 - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its first Phase III clinical trial with a...

Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, is to Commence Phase I Clinical Trial in Japan with CF101 for the Treatment of Rheumatoid Arthritis
August 17, 2008--Seikagaku Corporation (SKK), the exclusive licensee of Can-Fite's CF101 in the Japanese market, is about to commence phase I clinical trial in Japan with CF101 for the treatment of rheumatoid arthritis....

ETEX Corporation Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
CAMBRIDGE, Mass., August 15, 2008 -- ETEX Corporation, an advanced biomaterials company, announced today that it has launched an innovative orthobiologic, EquivaBone(TM). EquivaBone(TM) is a bone graft substitute that...

ETEX Corporation Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
CAMBRIDGE, Mass., August 15, 2008 -- ETEX Corporation, an advanced biomaterials company, announced today that it has launched an innovative orthobiologic, EquivaBone(TM). EquivaBone(TM) is a bone graft substitute that...

PRECISION V Results
August 15, 2008--Biocompatibles is pleased to announce the headline results from the PRECISION V clinical trial. A more complete presentation of the results will take place as planned at CIRSE (Cardiovascular and...

METHYLGENE PROVIDES UPDATE ON SUSPENSION OF NEW ENROLLMENT IN MGCD0103 CLINICAL TRIALS
Montreal, Quebec and Summit, NJ - August 15, 2008 - MethylGene Inc. (TSX:MYG) today announced that as a result of the internal voluntary suspension of enrollment of new patients into clinical trials evaluating MGCD0103,...

First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial
Audubon, Pa. (August 15, 2008) - Globus Medical, Inc., the largest privately held spinal implant manufacturer in the world, today announced that the first FLEXUS(TM) Interspinous Spacers have been implanted under an...

Evidence of activity seen in new data from ASA404 prostate cancer trial
London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc (LSE:ASM; USOTC: ATSMY) today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were...

Spectrum Pharmaceuticals Launches FUSILEV(TM)
IRVINE, Calif., Aug 15, 2008 -- Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) today launched FUSILEV(TM) (levoleucovorin) for injection.

VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Cranbury, NJ, August 14, 2008 - VaxInnate Corporation announced today that its M2e universal influenza vaccine candidate was safe and immunogenic in its first Phase I clinical trial, raising hopes for a universal...

Dendreon Initiates Second of Two New Phase 2 Trials
SEATTLE, WASHINGTON, August 14, 2008 -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated its second of two new Phase 2 trials of PROVENGE

BIOTRON EXPANDS HCV CLINICAL TRIAL TO A SECOND SITE
August 14, 2008--The Directors are pleased to advise that Biotron Limited ('Biotron') has expanded its Phase Ib/IIa clinical trial of BIT225 in Hepatitis C virus ('HCV') infected patients to include a second trial site....

Enrollment complete in Phase IIb AK clinical trial
EMERYVILLE, California and BRISBANE, Australia, 14 August 2008 Peplin, Inc. (ASX:PLI) today announced the completion of enrollment of its 240 patient phase IIb US and Australian clinical trial in actinic (solar)...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
SAN CARLOS, Calif., August 14, 2008 -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly produced...

Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)
August 14, 2008 -- Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported...

PROGEN RESUMES PHASE 1 DEVELOPMENT OF ANTI-CANCER AGENT, PG11047, IN COMBINATION
Brisbane, Australia. 14 August 2008. Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ:PGLA) today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its polyamine analogue...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
BETHESDA, Md., August 14, 2008 -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced...

OrthoLogic Announces Completion of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
TEMPE, Ariz., Aug. 14, 2008 -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the completion of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring. Patient follow-up is ongoing.

Isis Initiates Clinical Trial of CRP Drug
CARLSBAD, Calif., August 13, 2008 -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP)....

Encorium Group Signs $3.5 Million of New Contracts for Vaccines Clinical Trials $13.5 Million of New Business Contracts Announced During the Past Three Weeks
August 13, 2008 -- WAYNE, Pa.-- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials...

BIOTRONIK announces positive interim results for its PRO-Kinetic Coronary Stent clinical study
August 13, 2008--Buelach, Switzerland. BIOTRONIK welcomed the interim results from the prospective, multicenter, single-arm study that demonstrates efficacy and safety of BIOTRONIK's PRO-Kinetic Coronary Stent System....

Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer Commences
NEW YORK-- August 13, 2008--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been...

APOSENSE
Louvain-la-Neuve, Belgium and Petach-Tikva, Israel, August 13, 2008 -- IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) the leading global provider of PET radiopharmaceuticals, and NST...

VivaGel
Melbourne Australia; 13 August 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the start of its next clinical trial of VivaGel

Lexicon Pharmaceuticals Identifies New Drug Candidate for Glaucoma
The Woodlands, Texas, August 13, 2008 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it...

Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
LA JOLLA, Calif., Aug. 12 -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA - News; "Duska") announced today that it has received comments from the U.S. Food and Drug Administration's (the "FDA") Division of...

Altus Pharmaceuticals Inc. (ALTU) Cystic Fibrosis Trial Meets Goal but Results Not as Hoped
CAMBRIDGE, Mass.-August 12, 2008---Altus Pharmaceuticals Inc. (NASDAQ: ALTU - News) announced today that its Phase 3 efficacy trial of TrizytekTM (porcine-free enzymes) in patients with cystic fibrosis (CF) successfully...

Delcath Expands Phase III Trial for Metastatic Melanoma to Include John Wayne Cancer Institute in California
NEW YORK, NY Aug 12, 2008 -- Delcath Systems, Inc. (NasdaqCM:DCTH) announced today that the John Wayne Cancer Institute ("JWCI"), at Saint John's Health Center in Santa Monica, California, has joined Delcath's Phase III...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
EMERYVILLE, Calif., Aug 12, 2008 -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of...

EPIX Pharmaceuticals Initiates Phase 2b Right-Heart Catheterization Study of PRX-08066 in Patients with Chronic Obstructive Pulmonary Disease and Moderate-to-Severe Pulmonary Hypertension
LEXINGTON, Mass.-- August 12, 2008--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
PRINCETON, N.J., August 12, 2008 -- Medarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic...

Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid® Lotion 0.1%
Cranford, NJ (PRWEB) August 12, 2008 -- A new product to treat atopic dermatitis in adult to pediatric patients as young as three months of age was recently introduced. Locoid Lotion, launched by Triax Pharmaceuticals,...

Algeta begins first US clinical trial of Alpharadin in men with advanced prostate cancer
Oslo, Norway, 12 August 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, has started the first US clinical trial for its lead product Alpharadin in men with hormone-refractory prostate cancer (HRPC)...

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
San Diego, August 12, 2008 - Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company, announced the publication of three clinical trials on the use of OraVerse (phentolamine mesylate) injection as a...

MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha
GAITHERSBURG, Md., August 12, 2008 -- MedImmune today announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with...

Alnylam and Collaborators Publish New Pre-Clinical Research on RNAi-Mediated Silencing of PCSK9, a Genetically Validated Regulator of LDL Metabolism
CAMBRIDGE, Mass., Aug 12, 2008 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that new pre-clinical data from its hypercholesterolemia program was published in...

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us